



Drug Delivery to Brain Tumors

Guest Editors:

Prof. Dr. Waldemar Debinski

Brain Tumor Center of
Excellence, Department of
Cancer Biology, Wake Forest
University School of Medicine,
Comprehensive Cancer Center of
Wake Forest Baptist Medical
Center, Winston-Salem, NC
27157, USA

Prof. Dr. Michael Vogelbaum

Program Leader of
NeuroOncology and Chief of
Neurosurgery, Department of
NeuroOncology, Moffitt Cancer
Center, Tampa, FL, USA

Deadline for manuscript
submissions:

closed (30 November 2020)

Message from the Guest Editors

Dear Colleagues,

Clinical outcomes following treatment of primary malignant brain tumors are far from satisfactory. One of the main obstacles to the development of effective therapies is failure to achieve therapeutically relevant concentrations in the CNS due to the presence of blood–brain and/or blood–brain–tumor barriers. Some of the approaches explored to address this challenge include blood–brain barrier disruption and drug modifications to enhance CNS permeability; unfortunately, neither approach has proven successful. Another approach is to deliver therapeutics locoregionally, directly into the tumor mass and surrounding tumor-infiltrated brain parenchyma. The most widely used method for direct brain delivery is convection-enhanced delivery (CED), whereby specially designed catheters are introduced into target tissue and the infusate is delivered slowly over a prolonged period of time. CED enables delivery of conventional, nano-, bio-, gene, and even cellular therapies. This Special Issue provides a highlight of the most recent progress made to improve the efficacy of therapeutics delivered directly to brain tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma